FORA Capital’s Pacira BioSciences PCRX Stock Holding History

FORA Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,457	Closed	-$235K	–	654
2025 Q1	$235K	Buy	+9,457	New	+$226K	0.02%	429
2024 Q4	–	Sell	-28,614	Closed	-$431K	–	542
2024 Q3	$431K	Buy	+28,614	New	+$489K	0.05%	313
2022 Q2	–	Sell	-8,131	Closed	-$615K	–	627
2022 Q1	$615K	Buy	+8,131	New	+$542K	0.11%	249
2021 Q1	–	Sell	-287	Closed	-$17K	–	1016
2020 Q4	$17K	Sell	287 -137	-32%	-$8.02K	﹤0.01%	884
2020 Q3	$25K	Sell	424 -12,229	-97%	-$711K	0.02%	552
2020 Q2	$664K	Buy	12,653 +11,132	+732%	+$465K	0.23%	120
2020 Q1	$51K	Sell	1,521 -4,662	-75%	-$194K	0.01%	769
2019 Q4	$280K	Buy	+6,183	New	+$263K	0.03%	537

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

FORA Capital's PCRX Position: Q2 2025 in Review

FORA Capital sold out of Pacira BioSciences (PCRX) in Q2 2025, closing a stake of 9,457 shares — an estimated $235K sold.

FORA Capital first reported a position in PCRX in Q4 2019 and held it in 8 quarters. The position peaked at $664K in Q2 2020. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2025.

FORA Capital reported no remaining Pacira BioSciences position as of Q2 2025 after selling out during the quarter.
FORA Capital sold 9,457 Pacira BioSciences shares in Q2 2025, an estimated $235K.
FORA Capital first reported a position in Pacira BioSciences in Q4 2019 and held it in 8 quarters.
FORA Capital's Pacira BioSciences position peaked at $664K in Q2 2020.
233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2025.

Based on FORA Capital's 13F filing for Q2 2025, filed 13 Aug 2025.